Kasius JC, Kildal W, Vrede SW, Askautrud HA, Pradhan M, van Altena AM, Tobin KR, Knoll K, Reijnen C, Reimann S, Dackus G, Vlatkovic L, Huvila J, Steinlechner M, Tubita V, Gil-Moreno A, Snijders MPLM, Vos MC, Hveem TS, Asberger J, Zeimet AG, Matias-Guiu X, Lindemann K, Weinberger V, Visser NCM et al. (2025)
Surgical stage in the era of molecular profiling of endometrial cancer
Eur J Cancer, 233, 116164 (in press)
DOI 10.1016/j.ejca.2025.116164, PubMed 41385938

Wang Y, Van Nieuwenhuysen E, Revheim ME, Deroose CM, Eriksson AGZ, Eyjolfsdottir B, Van Gorp T, Baert T, Aksnes AK, Myren K, Vergote I, Bruland ØS (2025)
First experience with intraperitoneal ²²⁴Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer
Gynecol Oncol, 204, 158-164 (in press)
DOI 10.1016/j.ygyno.2025.11.018, PubMed 41349345

Harter P, Marmé F, Redondo A, Reuss A, Lindemann K, Kurzeder C, Van Nieuwenhuysen E, Marth C, Pietzner K, Ray-Coquard I, Garcia-Duran C, Jonuskiene G, Heitz F, Béllier C, Pérez-Fidalgo JA, El-Balat A, Selle F, Romero I, Wimberger P, Follana P, Pardo B, de Gregorio N, Joly F, Gaba L, Burges A et al. (2025)
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
J Clin Oncol, JCO2501210 (in press)
DOI 10.1200/JCO-25-01210, PubMed 41337696